Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Therapies targeting somatic bystander genetic events represent a new avenue for cancer treatment. We recently identified a subset of colorectal cancer (CRC) patients who are heterozygous for a wild-type and a low activity allele (NAT2*6) but lack the wild-type allele in their tumors due to loss of h...

Descripción completa

Detalles Bibliográficos
Autores principales: Rendo, Veronica, Kundu, Snehangshu, Rameika, Natallia, Ljungström, Viktor, Svensson, Richard, Palin, Kimmo, Aaltonen, Lauri, Stoimenov, Ivaylo, Sjöblom, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775439/
https://www.ncbi.nlm.nih.gov/pubmed/33384440
http://dx.doi.org/10.1038/s41598-020-80288-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775439/
https://www.ncbi.nlm.nih.gov/pubmed/33384440
http://dx.doi.org/10.1038/s41598-020-80288-z

Ejemplares similares